06 August 2025
06 August 2025
H1 sales growth for Novo’s segment that includes Ozempic and Wegovy was down from the same period in 2024.
Staving off headwinds from Ibrance generic competition, Pfizer’s Q2 earnings surpassed analyst estimates.
The deal disrupts a long-established practice of the exemption of medicines from tariffs due to their importance in public health.
The company has so far filed 132 complaints in federal courts across 40 US states.
Vedolizumab is a biologic therapy indicated for treatment of ulcerative colitis and Crohn’s disease.
The immunisation programme aims to reduce rising gonorrhoea rates and address antibiotic-resistant strains.
For investors looking for stability and innovation, APAC-based biotech companies in Singapore, South Korea and Japan may be of interest.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
